Overview

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Status:
Recruiting

Trial end date:
2031-03-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

Phase:

Phase 1

Details

Lead Sponsor:

Hummingbird Bioscience

Treatments:

Docetaxel
Gemcitabine
Paclitaxel